Lyell Immunopharma Inc. (LYEL) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Lyell Immunopharma Inc.

    NASDAQ: LYEL · Real-Time Price · USD
    13.03
    0.88 (7.24%)
    At close: Sep 08, 2025, 3:59 PM

    Lyell Immunopharma Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 61K 130K 84.68M 10.65M
    Cost of Revenue
    		 n/a n/a 16.47M 14.54M
    Gross Profit
    		 61K 130K 68.22M -3.88M
    Operating Income
    		 -358.75M -247.01M -183.12M -214.78M
    Interest Income
    		 24.07M 23.45M 7.05M 1.17M
    Pretax Income
    		 -342.99M -234.63M -183.12M -250.22M
    Net Income
    		 -342.99M -234.63M -4.75M -285.5M
    Selling & General & Admin
    		 52.04M 66.98M 117.31M 89.06M
    Research & Development
    		 171.6M 182.94M 159.19M 138.69M
    Other Expenses
    		 135.17M -2.79M 1.89M -2.32M
    Operating Expenses
    		 358.82M 247.14M 276.5M 225.43M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 358.82M 247.14M 276.5M 225.43M
    Income Tax Expense
    		 n/a n/a -178.36M 35.28M
    Shares Outstanding (Basic)
    		 261.48M 250.98M 247.08M 242.74M
    Shares Outstanding (Diluted)
    		 261.48M 250.98M 247.08M 242.74M
    EPS (Basic)
    		 -1.31 -0.93 -0.74 -1.03
    EPS (Diluted)
    		 -1.31 -0.93 -0.74 -1.03
    EBITDA
    		 -200.64M -226.76M -166.65M -199.94M
    EBIT
    		 -220.27M -247.01M -187.06M -214.78M
    Depreciation & Amortization
    		 19.63M 20.25M 16.47M 14.54M

    Add to Watchlist